I think we need to be mindful though that Qbrexza didn't sell in Japan previously, which is supposed to be BOT's closest competitor in the US.
Also, Qbrexza only sold $25m in the US last FY, so it would seem that even though Ecclock did well in Japan, it does seem BOT are expecting quite a take-up of SB in the US. I'm not sure their $100m is realistic. Don't get me wrong, I would love it to be $100m turnover within a year, but I expect that is years and years down the track.
Then again, maybe Qbrexza is an absolutely crap product in the hyperhidrosis world and we'll see SB sold at record levels.
I think we need to be mindful though that Qbrexza didn't sell in...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $574.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.5¢ | 35.5¢ | $6.090M | 16.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 101678 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 79000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |